These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30032830)

  • 1. Effects of crizotinib on creatinine clearance and renal hemodynamics.
    Meijer-Schaap L; Van Putten JWG; Janssen WMT
    Lung Cancer; 2018 Aug; 122():192-194. PubMed ID: 30032830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate.
    Camidge DR; Brosnan EM; DeSilva C; Koo PJ; Chonchol M
    J Thorac Oncol; 2014 Nov; 9(11):1634-7. PubMed ID: 25436798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.
    Camidge DR; Kim EE; Usari T; Polli A; Lewis I; Wilner KD
    J Thorac Oncol; 2019 Jun; 14(6):1077-1085. PubMed ID: 30822515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Mizugaki H; Hamada A; Shibata T; Hosoda F; Nakamura H; Okuma Y; Shukuya T; Umemura S; Horiike A; Fukui T; Kogure Y; Daga H; Urata Y; Yamada K; Saeki S; Fujisaka Y; Nakamura Y; Sato M; Yoshida T; Hotta T; Oizumi S; Fujiwara Y; Ohe Y; Fujiwara Y
    Lung Cancer; 2019 Feb; 128():20-25. PubMed ID: 30642448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib.
    Iriagac Y; Cavdar E; Karaboyun K; Tacar SY; Akkoc Mustafayev FN; Celik E; Avci O; Okutur SK; Koral L; Demirci NS; Ozgun A; Seber ES
    J Cancer Res Ther; 2023; 19(2):376-381. PubMed ID: 37313913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
    Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
    Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Injury during Long-Term Crizotinib Therapy.
    Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Fujimoto H; Ito K; Nishii Y; Nishihama K; Baffour Tonto P; Takeshita A; Toda M; Gabazza EC; Taguchi O; Yonemura S; Hataji O
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of renal cyst in a NSCLC patient treated with crizotinib.
    Okauchi S; Kawai K; Miyazaki K; Yamada H; Satoh H
    Adv Respir Med; 2019; 87(3):201-202. PubMed ID: 31282565
    [No Abstract]   [Full Text] [Related]  

  • 9. Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
    Chen MF; Harada G; Liu D; DeMatteo R; Falcon C; Wilhelm C; Kris MG; Drilon A; Gutgarts V
    J Thorac Oncol; 2024 Jan; 19(1):153-159. PubMed ID: 37748692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS
    Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brigatinib versus crizotinib for ALK-positive NSCLC.
    Stirrups R
    Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
    Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
    Fokkema E; de Vries EG; Meijer S; Groen HJ
    Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
    Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
    Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
    Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
    Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.